Daily filing brief

6 Important BSE and NSE Announcements — 24 June 2026

Here are 6 notable company announcements from 24 June 2026. The brief brings the key developments together in one place and keeps the essential details easy to scan.

By Daily BrieferPublished

  1. Aye Finance Ltd

    Ind-Ra upgrades Aye Finance to IND A+/Stable; CP to IND A1+

    Credit Rating

    Rating actions and instrument details

    • Issuer rating upgraded to IND A+/Stable from IND A/Stable.
    • CP rating raised to IND A1+ from IND A1.
    • Bank loan facilities upgraded to IND A+/Stable.
    • Non-convertible debentures upgraded to IND A+/Stable; size reduced to INR 12,963.09m.
    • Outlook remains Stable; upgrade driven by capitalisation and funding diversification.

    Rationale, liquidity and financials

    • IPO-driven capitalisation improved tangible net worth to INR 24.75b.
    • AUM stands at INR 70.44b; secured loans ~60% of portfolio.
    • Adequate liquidity with unencumbered cash around INR 7.6b; diversified funding.
    • Covenant breaches exist in 9.2% of total borrowings; waivers have been obtained.
    • NPA 4.77%; leverage 2.03x; Tier 1 42.24%.

    Outlook and sensitivities

    • Outlook: Stable.
    • Material changes since last: issuer and CP upgrades; NCD size reduced.
    • Upgrade possible with continued growth, diversification, and stable long-term funding.
    • Downgrade risk if funding dries up, leverage exceeds 4x, or asset quality deteriorates.
    Read the primary exchange filing

  2. Biocon Ltd

    Duopharma Biotech secures insulin tenders from Malaysia MoH; Biocon unit to supply insulin products

    Press Release / Media Release

    Key contract wins

    • Duopharma Biotech via Duopharma (M) Sendirian Berhad secures insulin contracts from Malaysia MoH worth over MYR 225 million.

    Contract details

    • 3-year contract for human insulin: ~ MYR 155.27 million.
    • 2-year contracts for insulin glargine: ~ MYR 18 million; insulin aspart: ~ MYR 52.5 million.

    Biocon role

    • Biocon Sdn. Bhd. to supply short-acting insulin, insulin glargine, and insulin aspart to Duopharma (M) Sendirian Berhad.

    Strategic context

    • Johor facility enables scale manufacturing and broader patient access in Malaysia.
    Read the primary exchange filing

  3. Shilpa Medicare Ltd

    Shilpa Biologicals commissions ADC GMP manufacturing facility; fully operational with GMP qualification underway

    Press Release / Media Release

    Facility update and strategic context

    • Shilpa Biologicals Pvt Ltd, a Shilpa Medicare subsidiary, commissioned an ADC GMP manufacturing facility.
    • Facility is fully operational; GMP qualification protocols are underway.
    • Designed to meet US FDA, EMA, and major health authority requirements.
    • End-to-end ADC Drug Substance development and manufacturing including payload synthesis, linker development, mAb production, conjugation, purification.
    • Positions Shilpa as a cost-competitive, fully integrated ADC CDMO partner.
    • Supports Shilpa Medicare's strategy to expand high-potency biologics and oncology drug substances.
    Read the primary exchange filing

  4. Shri Bajrang Alliance Ltd

    Credit rating downgraded for Shri Bajrang Alliance Limited bank facilities to IVR BBB-/Stable

    Credit Rating

    Rating action and details

    • Long-term rating downgraded to IVR BBB-/Stable for Rs 25 crore bank facilities.
    • Agency: Infomerics Valuation and Rating Ltd; rating letter dated 23 June 2026.
    • Rating valid for one year from the rating committee date.
    • Rationale cites FY26 developments and review of operational and financial performance.
    • Instrument: bank facilities (cash credit) Rs 25 crore; facility with HDFC Bank.
    • Outlook: Stable; no change beyond the assigned Stable outlook.
    • Surveillance: annual review; NDS and quarterly data to be provided.
    Read the primary exchange filing

  5. AXIS Bank Ltd

    S&P Global Ratings assigns BB- to Axis Bank Gift City Branch AT1 Notes and BBB to GMTN Senior Notes

    Credit Rating

    Rating actions and instruments

    • BB- assigned to Axis Bank Gift City Branch AT1 Notes under GMTN.
    • BBB assigned to Axis Bank Gift City Branch Senior Notes under GMTN.
    • Issuer Rating BBB for Axis Bank Gift City Branch.

    Instruments/Facilities Rated

    • GMTN AT1 Notes – BB-.
    • GMTN Senior Notes – BBB.
    • Issuer Rating BBB (Gift City Branch).

    Rating Agency

    • S&P Global Ratings.

    Rationale

    • Rationale letters attached; detailed rationale not included in this chunk.

    Material changes

    • New ratings issued; no prior rating changes disclosed in this chunk.
    Read the primary exchange filing

  6. AXIS Bank Ltd

    Moody's assigns Baa3 rating with Stable outlook to Axis Bank GMTN senior notes

    Credit Rating

    Rating Action Details

    • Moody's assigns Baa3 rating with Stable Outlook to Axis Bank GMTN senior notes.
    • GMTN programme overall; Series 10 notes USD 300m rated Baa3 with Stable Outlook.
    • Rationale letter attached; explicit rating sensitivities are not disclosed.
    Read the primary exchange filing